MediPharm Labs Enters Into $4.68M Purchase Agreement For The Sale Of Australian Facility

MediPharm Labs Corp. (OTCQX: MEDIF ) (TSX:LABS) (FSE:MLZ) a pharmaceutical company specialized in precision-based cannabinoids, has entered into a s hare p rchase a greement with OneLife Botanicals PTY for the sale of MediPharm Labs Australia Pty Ltd , a wholly-owned subsidiary of the company, for a minimum value of AU $6.9 million ($4.68 million). The agreement is subject to routine conditions and is anticipated to close within 90 days. The agreement includes the assets of MPLA, specialized licensing, operational knowledge, and Australian and New Zealand customers currently served from that facility. All international contracts outside of Australia and New Zealand will remain with MediPharm Labs and be serviced from our Barrie GMP facility. In July 2021, MediPharm Labs was the first purpose-built cannabis facility to receive a pharmaceutical Drug Establishment License . Awarded by ... Full story available on Benzinga.com